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gA-mediated  anti-glomerular  basement  membrane
isease. A  case  reportnfermedad  mediada  por  autoanticuerpos  IgA  anti-membrana  basal
venous cyclophosphamide (CYC) (1 g the ﬁrst day) and steroids
(methylprednisolone, 1 g/day) during 3 days, and continued
with oral prednisone 60 mg/day.lomerular
ear Editor,
nti-glomerular basement membrane disease (anti-GBM) is
 rare disease usually mediated by IgG autoantibodies. It
sually presents as rapidly progressive glomerulonephritis,
ften accompanied by pulmonary hemorrhage.1 The hallmark
f anti-GBM disease are the blood circulating and tissue-
ound autoantibodies that target antigenic sites within the
lomerular basement membrane (GBM) and sometimes alve-
lar basement membranes.2
We  present a rare case of anti-GBM disease mediated by
gA autoantibody. A 65-year-old-man presented with gross
aematuria and nephrotic range proteinuria and was admit-
ed to the hospital.
His medical history included meningitis in childhood,
besity (BMI 47.53 kg/m2), glucose intolerance, hypertension,
ypercholesterolemia, duodenal ulcers, liver hemangioma
nd rectal polyps. He lost 12 kg during the last 3 months and
uffered from dysuria, pollakiuria and nocturia. Medications
ere: amlodipine and valsartan, moxonidine, torasemide,
ebivolol, atorvastatin, meloxicam and tramadol with parac-
tamol.
Upon admission his blood pressure was 150/80 mmHg.
e had pretibial edemas. Ultrasound examinations showed
ormal kidneys. Laboratory investigation revealed negative
ANCA, pANCA, ANA, ENA, anti-dsDNA and antiphospholipid
ntibodies along with normal C3 and C4 levels. Urine and
erum electrophoresis showed no monoclonal IgA, kappa or
ambda light chains. Routine enzyme-linked immunosorbent
ssay (ELISA) targeting IgG circulating anti-GBM autoanti-
odies were negative. Urine examination revealed proteinuria
f nephrotic range (11.8 g/day), haematuria with dysmorphic
rythrocytes and leukocyturia. His serum creatinine level
aised from 98 to 313 mol/L in two months and serum pro-Please cite this article in press as: Bacalja J, et al. IgA-mediated anti-glom
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eins were low. Chest X-ray showed bilateral pleural effusion
nd voluminous hiluses. He had partial respiratory insufﬁ-
iency with SO2 94%.Renal biopsy was performed. Light microscopy demon-
strated focal necrotizing crescentic glomerulonephritis with
cellular and ﬁbrous crescents (Fig. 1). 40% of glomeruli were
globally sclerotic. Immunoﬂuorescence microscopy demon-
strated linear (2+) staining along the glomerular capillary
loops for IgA (Fig. 2) along with weak linear staining for IgG,
anti-kappa and anti-lambda antibodies. Interstitial ﬁbrosis
and tubular atrophy occupied 40% of renal parenchyma. By
electron microscopy there were no immune complex-type
deposits. The ﬁndings were consistent with IgA-mediated
anti-GBM disease.
The patient had 12 plasma exchanges during a 1 month
time, along with albumin substitution. He was given intra-erular basement membrane disease. A case report. Nefrologia. 2017.
Fig. 1 – Light microscopy: glomerul with necrosis and
cellular crescent (×400, Periodic acid – Schiff stain).
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Fig. 2 – Immunoﬂuorescence microscopy: intense linear
rstaining along the glomerular capillary loops for IgA (×400).
Two months after the diagnosis of IgA-mediated anti-GBM
disease the patient had serum creatinine level 258 mol/L and
proteinuria of 4.6 g/day. He continued albumin substitution
and oral prednisone (60 mg/day) therapy. He was given another
cycle of CYC, but the therapy was stopped because of sepsis.
He started chronic hemodialysis 3 months after the onset of
the disease.
As our case demonstrated, standard assays used for detec-
ting circulating IgG anti-GBM antibodies can perceive only IgG
and they will fail to detect IgA anti-GBM antibodies. Thus the
recognition of the disease depends on linear staining of IgA
on glomerular basement membranes detected using immu-
noﬂuorescence microscopy on the kidney biopsy.3,4
In IgA-mediated anti-GBM disease antigens belong to 5
and 6 chains of type IV collagen. That differs from antin-
gens belong to 3 or 5 chains of type IV collagen found in
IgG-mediated anti-GBM disease.5
The patient we  presented did not had signs of alveolar
hemorrhage. In previously described cases of IgA-mediated
anti-GBM disease pulmonary involvement was found in
5 cases.1,4,6–8
Major predictors of piteous renal outcome in anti-GBM dis-
ease are high serum creatinine level (≥5.7 mg/dL, 503.9 mol/L)
and many  circumferential crescents.9 Comparing to the
IgG-mediated anti-GBM disease, prognosis of IgA-mediated
anti-GBM disease is poor.3,4 Renal function usually does never
improve and in most cases the disease leads to the end-
stage renal failure.1,3,4 Also, 2 patients described in previous
reports died because of uncontrolled alveolar hemorrhage6
and pneumonia.10
Classically, IgA-mediated anti-GBM disease is treated in
the same way as its IgG counterpart, with the triple regimen
of plasmapheresis, steroids and oral CYC.1,3,4 Whether this
intensive treatment is the best option in IgA-mediated anti-
GBM disease is unknown as this approach was used in only
few cases and in all described cases the patients developed
ESRD.1,3–5Please cite this article in press as: Bacalja J, et al. IgA-mediated anti-glom
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Kidney transplantation is the treatment of choice for
patients who develop ESRD caused by anti-GBM disease.
In 2 previously described cases of IgA-mediated anti-GBM x x(x x):xxx–xxx
disease the patients underwent renal transplantation. In the
report by Moulis et al.3 there was no recurrence of the disease
5 months after transplantation. In other case1 the
disease was secondary to a plasma cell dyscrasia. The
disease recurred and caused the loss of the allograft 2 years
after the transplantation.
In order to make the right diagnosis, performing the renal
biopsy is essential in cases of rapidly progressive glomeru-
lonephritis. Early diagnosis of IgA-mediated anti-GBM disease
can ensure the treatment in earlier stages of the disease and
ESRD can possibly be prevented or at least delayed. As cur-
rent treatment regimens result in poor prognosis, the disease
might require more  speciﬁc treatment strategy, distinct from
the therapy for IgG anti-GBM disease.
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